Introduction
============

Among the four species of human plasmodia, *Plasmodium vivax* and *P. ovale* are associated with relapse episodes. Precise discrimination between such phenomenon and re-infection or treatment failure cases in malarious areas particularly in transmission seasons cannot be easily performed unless employing new and advanced bio-molecular techniques that are accounted to be relatively helpful.

Although *P. vivax* is known as the cause of benign tertian malaria increasing evidences suggest that life-threatening complications of the parasite are more common than previously thought. *P. vivax* is the major agent of malaria morbidity in Asia and the second most prevalent plasmodium in the most of malarious regions ([@b21-ijad-4-24], [@b18-ijad-4-24], [@b10-ijad-4-24]). Widely distribution of *P. vivax* and existence of relapse behavior in the parasite emphasize the importance of considering the relapse phenomenon particularly after radical treatment. A number of studies have been carried out to explore the nature of relapse using various methods. It has been known that manifestation of relapse in *P. vivax* depends on variation of the parasite strains ([@b5-ijad-4-24]). The Chesson strain an example of tropical zone strains relapses with short intervals almost one month during the year ([@b4-ijad-4-24]). The St. Elizabeth strain of *P. vivax* with 6 to 14 mo latent period belongs to temperate zone strains that are the second pattern of relapse activity ([@b17-ijad-4-24], [@b14-ijad-4-24]). The manifestation of relapse in this pattern renewed during long intervals ([@b5-ijad-4-24]). In addition to the two main mentioned patterns of relapse activity, an intermediate form also has been reported ([@b1-ijad-4-24]).

Beside the relapse activity in *P. vivax*, renewed attack is also suspected as a re-infection or treatment failure in malarious areas such as Iran located in Middle East region. In 2008, approximately 11460 Malaria cases were microscopically diagnosed in Iran, which 90% of them were detected as *P. vivax* ([@b2-ijad-4-24]). A retrospective epidemiological study based on the biodata surveillance forms including radical treatment data at a limited part of southeastern Iran showed that the relapse risk of *P. vivax* were 16.8% and 24.5% depending on one or two years after primary attack respectively ([@b9-ijad-4-24]).

Since radical treatment of vivax malaria is precisely employed on the malarious areas of Iran results of the study stimulated us to evaluate the relapse risk of vivax malaria in Hormozgan Province, a malarious area of southeastern Iran using *P. vivax* merozoite surface protein 1 (pvMSP1), as a useful genetic marker for genotyping- *P. vivax* isolates ([@b7-ijad-4-24], [@b22-ijad-4-24]).

Materials and Methods
=====================

Study sites and sample collection
---------------------------------

This study was conducted in urban health centers of Bandar-Abbas, Minab, Bandar-Jask and Bashagard districts of Hormozgan Province, southeast of Iran from January 2008 to March 2009 for consideration as a case- series study.

The first three districts have hot and humid weather with year round transmission of malaria parasites, but two main peaks are on May to August and October to November. Bashagard district has temperate climate in winter with average temperature of 13.5° C (Min.5° C and Max.22° C) and warm weather in summer with average temperature of 36° C (Min.32° C and Max.40° C).Transmission pattern of malaria in Bashagrd is, more or less, the same as above-mentioned districts. *Plasmodium vivax* and *Anopheles stephensi* are the predominant species of parasite and vector in those areas respectively. A total of 95 symptomatic vivax malaria infected patients after preparing an informed consent from each of them or their parents, were enrolled for the consideration. Pregnant women, patients below 4 yr of age and those who were unavailable for the follow up duration (9 months) were excluded from the study. Ethical permission for the study was approved by Tehran University of Medical Sciences Ethical Committee. A 2-ml venous blood from each patient was sampled into an EDTA contained tube. Prior to sampling, all isolates were diagnosed as *P. vivax* by light microscopical examination of Geimsa-stained thick blood smears. All samples were frozen and stored at −20° C until DNA purification. Following blood sampling the patients received 25 mg/kg chloroquine divided over three days and 0.75 mg/kg primaquine from day 3 onwards weekly for 8 consecutive weeks as a standard radical treatment of vivax malaria. The enrolled patients were followed up by microscopical examination of their blood thick smears bimonthly during next nine months for probable renewed manifestation. Moreover, the registered patients were asked to contact us if they felt fever or any other symptoms at any time. Parasite density for each sample was measured as the number of parasite per microlitre of blood in thick blood smear.

Genomic DNA purification
------------------------

DNA was extracted from *P. vivax* infected whole blood samples using a commercial genomic DNA purification kit (QIAGEN) according to the manufacturer\'s instructions.

Polymerase chain reaction (PCR) amplification
---------------------------------------------

A polymorphic region of pvMSP1, where widely has been used for molecular analysis of relapse cases ([@b7-ijad-4-24], [@b12-ijad-4-24], [@b3-ijad-4-24], [@b11-ijad-4-24]) was selected and a PCR method was employed for all the samples to amplify a specific variable gene fragment. This gene fragment is located between two interspecies conserved blocks named: ICB5 and ICB6. The mentioned blocks are usually used as genetic marker for differentiation of *P. vivax* species. One pair of oligonucleotid primers, designed previously ([@b7-ijad-4-24], [@b12-ijad-4-24]), were synthesized according to the mentioned conserved sequences as follows: 5′- TACTACTTGATGGTCCTC-3′; 5′- CCTT-CTGGTACAGCTCAATG-3′. PCR amplification were performed in 20μl of reaction mixture containing 2 μl premix (Titan Hot Tag Bioatlas), 20 pmol of each primer, 5 μl DNA template and 9 μl distilled water. The amplification was composed of an initial denaturation for 5 min at 94° C, which followed with 35 cycles of 94° C for 30 seconds, 58° C for 1 min and 72° C for 1 min and 30 seconds. The reaction was stopped after a final extension process for 10 min at 72° C. PCR products were analyzed by performing gel electrophoresis on a 1% agarose gel using 100 bp DNA marker (Fermentase). After visualization of the ethidium bromide- stained gels under UV light, the products were estimated to be approximately 680 bp. The obtained fragments were sequenced by SEQLAB in Germany ([www.SEQLAB.de](www.SEQLAB.de)). The resultant sequences of PCR fragments were analyzed in NCBI (NCBI, NIH, USA). Both nucleotide and amino acid sequences for each PCR product of primary and secondary infections have been considered for returned patients.

Nucleotid sequences of the pvMSP1 have been submitted to the National Centre of Biotechnology Information Gene Bank and are available for public access under accession numbers GQ403477, GQ403478, GQ403480 and GQ403481 for the Bandar- ask isolates and GQ403479 for the Bashagard isolate.

Results
=======

During the nine months follow up three cases (3.2%) of 95 *P. vivax* infected patients experienced a second attack on 83--199 days after the initial episode of infection respectively ([Table 1](#t1-ijad-4-24){ref-type="table"}).

The amplified segment of pvMSP1 block 5 gene in returned patients displayed identical size approximately 680 basepairs for both primary and secondary isolates ([Fig. 1](#f1-ijad-4-24){ref-type="fig"}).

All five sequenced isolates in both directions revealed four distinct genotypes for pvMSP1. The rate of homology between primary and secondary isolates in each case at nucleotide and amino acid level is tabulated in [Table 2](#t2-ijad-4-24){ref-type="table"}. Sequencing results of 1P, 1S, 2P, 2S and 3P isolates, which were named pv-jask-1 to pv-jask-4 and pv-bashagard respectively in Genebank, showed an identity with BP13, T117, BP13, TC28 and Chesson genotypes respectively in checking with Genebank (NCBI, NIH, USA). Four isolates pv-jask-1 to pv-jask-4 showed close similarity to Salvador I (Sal-1) allelic type.

Alignment of nucleotide and their deduced amino acid between paired sequences of primary and secondary isolates revealed 8 and 6 dissimilarities for the first case, and also 9 and 7 for the second case in sequential characters respectively. Two nucleotide insertions encoding Q (CAA) occurred in pv-jask-1 and pv-jask-3 alleles at the beginning of the P-type part of sal-1 like sequence. Moreover, in both alleles a P to Q (CCA to CAA) and a H to Q (CAC to CAA) substitutions was observed in amino acid sequence. In each of pv-jask-2 and pv-jask-4 alleles a single nucleotide polymorphism (SNPs) has occurred in P-type part of sal-1 like sequence, V to A (GTA to GCA). In pv-jask-1, pv-jask-2, pv-jask-3 and pv-jask-4 alleles I to T (ATC to ACC), A to V (GCC to GTC) and E to Q (GAA to CAA) single nucleotide polymorphisms emerged at the same region of the gene.

Although microscopical examination of secondary thick blood smear of the third returned patient confirmed new *P. vivax* infection, the venous blood sample was accidentally missed.

Discussion
==========

Understanding the type of reappearing *P. vivax*, the main causative plasmodium for malaria outside Africa, at the same patient is a crucial recognition for combating vivax malaria at the endemic areas. Such phenomenon will be more important when we encounter with the new infection after a course of radical treatment. Relapses are a feature of *P. vivax* with at least one episode of recurrence because of activating dormant liver parasites (hypnozoites). They usually cause new clinical manifestations with a blood schizogonic pattern that are needed to be treated. Beside of the relapse, reinfection (resulting from a new infected mosquito biting) and recrudescence (originating from drug resistant asexual blood-stage parasites) subjects attract a number of relevant studies. Reports released from some malarious areas indicate many relapses with different features of recurrence ([@b7-ijad-4-24], [@b20-ijad-4-24], [@b8-ijad-4-24], [@b15-ijad-4-24], [@b9-ijad-4-24], [@b3-ijad-4-24]).

This study was designed to perform a comparative molecular analysis of paired primary and secondary *P. vivax* isolates that appear in the same patient following an 8 wk radical treatment. Three out of 95 patients experienced second episode of vivax malaria within 83--199 days after primary attack. DNA sequences analysis of two paired primary and secondary *P. vivax* isolates collected from two patients displayed that they were not identical. With referring to the results obtained in this study we encounter with four generic explanations for these results: The first probability is the recrudescence phenomenon. The new manifestation of *P. vivax* after primary attack in returned patients occurred on day 83 that usually is beyond the range of returning time for drug resistance at asexual blood-stage as defined ([@b19-ijad-4-24]), unless we imagine the emergence of some primaquine-resistant hypnozoites, but owing to lack of reasonable facts the imagination remains unclear. On the other hand, the patients were living in the malarious endemic areas where transmission of malaria potentially may occur over the year. Therefore, differentiation between recrudescence and reinfection may not be possible without some complementary considerations.Long incubation period, this phenomenon is one of the complicated propositions in *P. vivax* studies. Inoculation of mixed genotypes of *P. vivax* (multiple clone infections) with different incubation periods by vector(s) or multiple bites happening over a long period can confuse among real relapse, successive infections released from liver because of different incubation periods and reinfection. Besides the reason of endemicity, effective radical treatment of patients in this study seriously decreases the implementation of emergence of *P. vivax* with different incubation periods.Relapse phenomenon is another cause to explain the obtained results. Although relapse is put usually at the first line attribution to new infections of *P. vivax* particularly if a similar genotype would be considered between primary and secondary infections ([@b7-ijad-4-24]), some authors believe that parasites involved in relapse infection often bear a genotype different from those present at primary infection ([@b11-ijad-4-24], [@b13-ijad-4-24]). Results obtained in this study may at the first view indicate to relapses, but employing precise radical treatment against *P. vivax* and also endemicity of malaria in the studied areas weaken such indication.Reinfection is the fourth conception that draws a line of explanation about the reappearance of *P. vivax* in this study. In spite of either 14-day or 8-week radical treatment of vivax malaria at the endemic malarious areas those recurrences occur after day 30 or day 74 can be assumed mostly to be reinfection unless reasonable facts refuse the assumption.

According to our results, the nearest and latest recurrences occurred on 83 and 199 days after primary attack and other reasons mentioned above we adopt the reinfection of *P. vivax* as a resultant for both returned patients in this study. Leslie et al. in a comparative study between 14-day and 8-week *P. vivax* malaria treatment using primaquine as an antirelapse drug showed 1.8% and 5.4% treatment failure respectively ([@b16-ijad-4-24]). The latter failure is comparable with the results obtained in our study. The authors did not document how they could distinguish treatment failures from those that are new infections. Indeed, it is difficult to differentiate between either relapses and new infections or recrudescence by using current genotyping methods without including a number of aspects such as mixed genotyping markers and epidemiological features.

Although in this study recurrent venous blood sample of the third patient was lost accidentally, DNA sequencing of the primary sample surprisingly revealed a Chesson genotype *P. vivax* from Bashagard area with warm-dry and temperate climates in summer and winter respectively. This is the first report to our knowledge of Chesson type *P. vivax* from such climate.

Some authors, as cited above, believe that the hypnozoites induce relapses are similar to those parasites cause primary attack ([@b7-ijad-4-24]), but the question is that how we can differentiate between real relapses and reinfections or recrudescences. On the other hand, if the parasites in primary infections and relapses are genotypically identical why they follow different patterns of emergence particularly if genotype-specific immunity phenomenon that develops against primary blood- stage parasites ([@b11-ijad-4-24]) would be accounted.

More combined studies including epidemiological and genotyping considerations are needed to clarify the questions that have been released in this field.

We would like to thank Mr. GH Mohseni, Mrs. E Torabi, Mr. A Parekar, Mrs. M Shahrokhi, Mr. A Ramezanpour, Mr. A Ahmadi and Mr. M Safari for their technical cooperation and specific thanks to Dr. H. Hajjaran, Mrs. A. Motevalli, Dr. R. Safari and Mrs. L. Farivar for their usefull contribution in the study.

This study was supported financially by center of Infectious Disease Management in Iran and Tehran university of Medical Sciences. The authors declare that they have no conflicts of interest.

![Size polymorphism of both paired isolates. M fermentase marker, P as primary infection and R as recurrent infection. C+ as positive control. For 3R we could not extract DNA from prepheral blood smear.](ijad-4-24f1){#f1-ijad-4-24}

###### 

Characteristics of returned patients and their paired primary/ secondary samples

  **Patient isolate**   **Day/month/year**   **Age (year)**   **Area of aquisition**   **Parasitemia/μL of blood**
  --------------------- -------------------- ---------------- ------------------------ --------------------------------------------
  1P                    01/07/2008           **11**           Bandar - jask            13848
  1R                    05/11/2008                                                     15467
  2P                    25/08/2008           **9**            Bandar- jask             308
  2R                    16/11/2008                                                     231
  3P                    14/06/2008           **11**           Bashagard                [\*](#tfn1-ijad-4-24){ref-type="table-fn"}
  3R                    01/01/2009                                                     27

The rate of parasitemia was not known.

###### 

The rate of homology at nt^[∞](#tfn2-ijad-4-24){ref-type="table-fn"}^ and aa^[δ](#tfn3-ijad-4-24){ref-type="table-fn"}^ level

  **No**          **patient**      **Homology at nt level**   **Homology at a.a level**
  --------------- ---------------- -------------------------- ---------------------------
  1               1P (pv-jask-1)   98%                        97%
  1S(pv-jask-2)                                               
  2               2P(pv-jask-3)    98%                        96%
  2S(pv-jask-4)                                               

nt : nucleotide,

aa : amino acid
